Ivabradine

Ivabradine

Clinical data
Pronunciation	/ɪˈvæbrədiːn/
Trade names	Corlanor, Procoralan
AHFS/Drugs.com	International Drug Names
License data	EU EMA: Procoralan
Pregnancy category	AU: D
Routes of administration	Oral
ATC code	C01EB17 (WHO)
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	40%
Protein binding	70%
Metabolism	Hepatic (first-pass) >50%, CYP3A4-mediated
Biological half-life	2 hours
Excretion	Renal and fecal
Identifiers
IUPAC name 3-[3-({[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one
CAS Number	155974-00-8 N
PubChem CID	132999
IUPHAR/BPS	2357
ChemSpider	117373 Y
UNII	3H48L0LPZQ
KEGG	D07165 Y
ChEBI	CHEBI:85966 N
ChEMBL	CHEMBL471737 Y
Chemical and physical data
Formula	C27H36N2O5
Molar mass	468.585 g/mol
3D model (Jmol)	Interactive image
SMILES O=C2N(CCc1cc(OC)c(OC)cc1C2)CCCN(C[C@@H]4c3cc(OC)c(OC)cc3C4)C
InChI InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1 Y Key:ACRHBAYQBXXRTO-OAQYLSRUSA-N Y
NY (what is this?)

Ivabradine, marketed under the trade name Corlanor among others, is a medication used for the symptomatic management of stable heart related chest pain and heart failure not fully managed by beta blockers.

Ivabradine acts by reducing the heart rate via specific inhibition of the funny channel, a mechanism different from that of beta blockers and calcium channel blockers, two commonly prescribed antianginal drugs. Ivabradine is a cardiotonic agent.

It is used for the symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm who cannot take beta blockers. It is also being used off-label in the treatment of inappropriate sinus tachycardia.

It may be as effective as the beta blocker atenolol and comparable with amlodipine in the management of chronic stable angina.

It is used in combination with beta blockers in people with heart failure with LVEF lower than 35 percent inadequately controlled by beta blockers alone and whose heart rate exceeds 70 beats per minute. In people not sufficiently managed with beta blockers for their heart failure adding ivabradine decreases the risk of hospitalization for heart failure.

Ivabradine is contraindicated in sick sinus syndrome, and should not be used concomitantly with potent inhibitors of CYP3A4, including azole antifungals (such as ), macrolide antibiotics, nefazodone and the antiretroviral drugs nelfinavir and ritonavir.